Form 4: Avidity Biosciences Executive Sells Shares to Cover Tax Obligations After Performance-Based Stock Units Vest

Teresa McCarthy, Chief Human Resources Officer of Avidity Biosciences, sold shares to cover tax obligations following the vesting of performance-based restricted stock units (PSUs) due to the initiation of the Phase 3 HARBOR trial for del-desiran.

Summary

• On June 17, 2024, Teresa McCarthy, Chief Human Resources Officer of Avidity Biosciences, had 25,000 performance-based restricted stock units (PSUs) vest due to the achievement of a performance objective: the initiation of the Phase 3 HARBOR trial for del-desiran.
• To cover tax withholding obligations related to the vesting of these PSUs, McCarthy sold 9,864 shares of common stock on June 18, 2024, at a weighted-average price of $39.1294.
• The sale was mandated by Avidity Biosciences' equity incentive plans, which require tax obligations to be funded by a 'sell-to-cover' transaction.
• McCarthy also earned an additional 25,000 PSUs on June 17, 2024, which converted to time-based restricted stock units that will vest on December 17, 2024, subject to continued employment.
• Following these transactions, McCarthy beneficially owns 57,171 shares of Avidity Biosciences common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing primarily reflects routine transactions related to executive compensation and tax obligations. The vesting of PSUs tied to a clinical trial milestone is a positive indicator, but the subsequent sale of shares is a standard practice.

Positives

• The vesting of the PSUs indicates the achievement of a key company performance objective: the initiation of the Phase 3 HARBOR trial for del-desiran.

Future Outlook

The remaining 25,000 time-based restricted stock units will vest on December 17, 2024, subject to the Reporting Person's continued employment or service through such date.

Industry Context

This filing reflects routine insider transactions related to equity compensation. The vesting of PSUs tied to clinical trial milestones is common in the biotechnology industry, aligning executive compensation with company performance. The 'sell-to-cover' practice is also standard for managing tax obligations associated with equity awards.

Comparison to Industry Standards

• Many biotech companies, such as Alnylam Pharmaceuticals and Ionis Pharmaceuticals, utilize performance-based equity awards to incentivize executives to achieve key clinical and regulatory milestones.
• The 'sell-to-cover' method for tax obligations is a widely adopted practice among publicly traded companies, including those in the biotechnology sector.
• Executive stock ownership levels are generally comparable to industry peers, reflecting a balance between incentivizing performance and managing personal financial risk.

Stakeholder Impact

• The vesting of PSUs and subsequent sale of shares may have a minor impact on shareholders, but it is unlikely to be significant.
• The vesting of PSUs is a positive event for the employee, aligning their interests with the company's success.

Key Dates